Literature DB >> 7989315

Human immunodeficiency virus nucleocapsid protein accelerates strand transfer of the terminally redundant sequences involved in reverse transcription.

J C You1, C S McHenry.   

Abstract

During the initial stages of human immunodeficiency virus (HIV) replication, 5'-terminally redundant (R') DNA, the minus strand synthesized as the complement of the 5'-long terminal repeat (LTR) terminal redundancy, must anneal to the 3'-LTR RNA to enable template transfer. The (R')DNA sequences contain the site involved in the tat-TAR interaction and extensive secondary structures that strongly interfere with annealing. The novel annealing reaction between (R')DNA and 3'-LTR RNA follows first-order kinetics, consistent with an unusually slow unfolding of the secondary structure as the rate-limiting step followed by a more rapid nucleation step. The HIV nucleocapsid protein accelerates the annealing reaction 3000-fold under optimal conditions. This acceleration may be necessary for strand transfer to efficiently occur in vivo and may provide a target for anti-HIV chemotherapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989315

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  84 in total

1.  Effect of distance between homologous sequences and 3' homology on the frequency of retroviral reverse transcriptase template switching.

Authors:  K A Delviks; V K Pathak
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  In vitro evidence for the interaction of tRNA(3)(Lys) with U3 during the first strand transfer of HIV-1 reverse transcription.

Authors:  F Brulé; G Bec; G Keith; S F Le Grice; B P Roques; B Ehresmann; C Ehresmann; R Marquet
Journal:  Nucleic Acids Res       Date:  2000-01-15       Impact factor: 16.971

3.  The effect of mutations in the HIV-1 nucleocapsid protein on strand transfer in cell-free reverse transcription reactions.

Authors:  M Hsu; L Rong; H de Rocquigny; B P Roques; M A Wainberg
Journal:  Nucleic Acids Res       Date:  2000-04-15       Impact factor: 16.971

4.  The leader of the HIV-1 RNA genome forms a compactly folded tertiary structure.

Authors:  B Berkhout; J L van Wamel
Journal:  RNA       Date:  2000-02       Impact factor: 4.942

5.  Identification of residues of the Moloney murine leukemia virus nucleocapsid critical for viral DNA synthesis in vivo.

Authors:  J Gonsky; E Bacharach; S P Goff
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  Subtle alterations of the native zinc finger structures have dramatic effects on the nucleic acid chaperone activity of human immunodeficiency virus type 1 nucleocapsid protein.

Authors:  Jianhui Guo; Tiyun Wu; Bradley F Kane; Donald G Johnson; Louis E Henderson; Robert J Gorelick; Judith G Levin
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Utilization of nonviral sequences for minus-strand DNA transfer and gene reconstitution during retroviral replication.

Authors:  S R Cheslock; J A Anderson; C K Hwang; V K Pathak; W S Hu
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 nucleocapsid protein specifically stimulates Mg2+-dependent DNA integration in vitro.

Authors:  S Carteau; S C Batson; L Poljak; J F Mouscadet; H de Rocquigny; J L Darlix; B P Roques; E Käs; C Auclair
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

9.  Kissing complex-mediated dimerisation of HIV-1 RNA: coupling extended duplex formation to ribozyme cleavage.

Authors:  Nikolai Windbichler; Michael Werner; Renée Schroeder
Journal:  Nucleic Acids Res       Date:  2003-11-15       Impact factor: 16.971

10.  Mechanism analysis indicates that recombination events in HIV-1 initiate and complete over short distances, explaining why recombination frequencies are similar in different sections of the genome.

Authors:  Sean T Rigby; April E Rose; Mark N Hanson; Robert A Bambara
Journal:  J Mol Biol       Date:  2009-02-20       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.